- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
| home:protocol:olmesartan [12.03.2018] – [Cardiovascular disease] sallieq | home:protocol:olmesartan [02.25.2019] – [Kidney disease] sallieq | ||
|---|---|---|---|
| Line 170: | Line 170: | ||
| * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | ||
| * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed> | * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed> | ||
| - | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | + | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> |
| * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | ||
home/protocol/olmesartan.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.